|
|
Vaccine Detail
|
MUC1 mRNA/CTLA-4 siRNA Co-Delivery Mannose-Modified NLE Vaccine |
| Vaccine Information |
- Vaccine Name: MUC1 mRNA/CTLA-4 siRNA Co-Delivery Mannose-Modified NLE Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Type: mRNA/siRNA vaccine
- Status: Research
- Host Species for Licensed Use: Mouse
- Antigen: MUC1 (Monfaredan et al., 2025)
- Immunization Route: subcutaneous injection
- Description: A dual-delivery vaccine employing mannose-modified nanolipid-exosome (NLE) nanoparticles to co-deliver modified MUC1 mRNA and CTLA-4 siRNA for triple-negative breast cancer (TNBC) immunotherapy. The hybrid platform (90% exosomal membrane, 10% synthetic lipids) targets dendritic cells via mannose receptors, enabling in situ MUC1 antigen expression and simultaneous CTLA-4 checkpoint silencing. Vaccination with this platform may stimulate robust cytotoxic T-lymphocyte (CTL) responses against MUC1-expressing tumor cells while preventing T cell exhaustion through CTLA-4 pathway inhibition. MUC1, a tumor-associated mucin and membrane-bound glycoprotein expressed by most glandular and ductal epithelial cells, is overexpressed and aberrantly glycosylated in TNBC and other epithelial cancers such as those of the breast, prostate, and ovary. In 4T1 mouse models, the combination therapy significantly enhanced tumor-infiltrating CD8+ T cells compared to vaccine or siRNA monotherapies (p < 0.01), increased MUC1-specific IFN-? production (p < 0.01), and demonstrated robust antigen-specific cytotoxicity in vivo (p = 0.0015), with MUC1 protein expression confirmed in draining lymph nodes post-vaccination (Monfaredan et al., 2025).
|
| Host Response |
|
|
| References |
Monfaredan et al., 2025: Monfaredan A, Şen S, Fathi NK, Taştekin D, Hosseininasab A, Bozbey HU, Öncül O. Enhancing Antitumor Efficacy of MUC1 mRNA Nano-Vaccine by CTLA-4 siRNA-Mediated Immune Checkpoint Modulation in Triple Negative Breast Cancer Mice Model. International journal of molecular sciences. 2025; 26(17); . [PubMed: 40943370].
|
|
